Senzime's TetraGraph receives CE Mark

15th December 2017

Senzime AB

Enaie Azambuja

0 0

Datasheet

Lena Söderström, CEO of Senzime states, "The CE mark is a major milestone for Senzime, we will immediately commence the market roll-out of the TetraGraph system initially in Europe followed by the US and rest of the world. The TetraGraph will allow physicians to monitor the effects of neuromuscular blocking drugs perioperatively and ensure that patients can breathe spontaneously which will prevent complications and hence lower healthcare costs”.

The TetraGraph neuromuscular monitor is a system designed to address the needs of perioperative monitoring of physiologic data in surgical patients receiving general anesthesia and muscle relaxation using neuromuscular blocking drugs (NMBAs).

The TetraGraph stimulates a peripheral nerve and measures, analyses and displays the muscle function in surgical patients who receive NMBAs as part of their general anesthetic.

“We look forward to use the TetraGraph routinely, since the device is very easy to use, saves us time with the quick set-up and provides invaluable clinical information,” says Prof. Bela Fulesdi, Chairman of the Department of Anesthesiology and Intensive Care, Debrecen University Hospital, Debrecen, Hungary.

Every year, over 70 million surgical patients undergo general anesthesia and receive neuromuscular blocking drugs. Without objective monitoring (the ability to measure and analyse the evoked muscle responses) over 30% of these patients experience postoperative complications.

The TetraGraph system will enable physicians to assure sufficient return of neuromuscular function of patients, and avoid these postoperative complications.

Senzime has previously entered distribution agreements for TetraGraph in the UK, Ireland, Switzerland, Australia and New Zealand, and licensing agreements in Japan. Discussions are ongoing with distributors for additional markets and additional agreements are expected during the following quarter.